Liver biopsy is a useful predictor of response to interferon therapy in chronic hepatitis C

Histopathology

Volumn 32, Issue 5, 1998, Pages 454-461

  Kaserer, K ^a   Fiedler, R ^a   Steindl, P ^a   Muller Ch ^a   Wrba, F ^a   Ferenci, P ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Hepatitis C; Histology; Interferon ; Iron

Indexed keywords

RECOMBINANT ALPHA2B INTERFERON;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHRONIC HEPATITIS; DIAGNOSTIC VALUE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HEPATITIS C; HUMAN; IMMUNOTHERAPY; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AGED; BIOPSY; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; IRON; MALE; MIDDLE AGED; PROGNOSIS; RNA, VIRAL; TREATMENT OUTCOME;

HEPATITIS C VIRUS;

EID: 0031800754     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2559.1998.00413.x     Document Type: Article

References (40)

1. Davis GL, Balart LA, Schiff ER et al. Treatment of chronic hepatitis C with recombinant interferon alfa: A multicenter randomized, controlled trial. N. Engl. J. Med. 1989; 321; 1501-1506.
2. Di Bisceglie AM, Martin P, Kassianides C et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double blind. placebo controlled trial. N. Engl. J. Med. 1989: 321; 1506-1510.
3. Hoofnagle JH, Peters M, Mullen K et al. Randomized. controlled trial of recombinant human alfa interferon in patients with chronic hepatitis B. Gastroenterology 1988: 95; 1318-1325.
4. Rubin AR, Falestiny M, Malet PF. Chronic hepatitis C. Advances in diagnostic testing and therapy. Arch. Int. Med. 1994: 154; 387-392.
5. Bosh O, Tapia L, Quiroga JA, Carreno V. An escalating dose regimen of interferon alfa-2a in the treatment of chronic hepatitis C. J. Hepatol. 1993: 17; 146-149.
6. Cama C, Craxi F, Tinè F et al. Predictors of response to alfa-interferon in chronic hepatitis C. A multivariate analysis on 361 treated patients. Hepatol. 1992: 16; 131A. Abstract.
7. Chemello L, Alberti A, Rose K, Simmonds P. Hepatitis C serotypes and response to interferon therapy (letter). N. Engl. J. Med. 1994; 330; 143.
8. Jouet P, Roudot-Thoraval F, Dhumeaux D, Métreau JM. Comparative efficacy of interferon alfa in cirrhotic and noncirrhotic patients with non A, non B, C hepatitis. Gastroenterology 1994: 106; 686-690.
9. Orito E, Mizokami M, Nakano T et al. Serum hepatitis C RNA level as a predictor of subsequent response to interferon-alfa therapy in Japanese patients with chronic hepatitis C. J. Med. Virol. 1994; 44; 410-414.
10. Clemente MG, Congia M, Lai ME et al. Effect of iron overload on the response to recombinant interferon alfa treatment in transfusion dependent patients with thalassemia major and chronic hepatitis C. J. Pediatr. 1994: 125; 123-128.
11. Olynk JK, Reddy RK, DiBisceglie AM et al. Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C. Gastroenterology 1995: 108; 1104-1109.
12. Van Thiel D, Friedlander L, Fagiuoli S, Wright HI, Irisch W, Gavaler JS. Response to interferon alfa therapy is influenced by the iron content of the liver. J. Hepatol. 1994: 20; 410-415.
13. Ishak K, Baptista A, Bianchi L et al. Histological grading and staying of chronic hepatitis. J. Hepatol. 1995; 22; 696-699.
14. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J. Hepatol. 1991: 13; 372-374.
15. Di Bisceglie AM, Axiotis CA, Hoofnagle JH, Bacon BR. Measurement of iron status in patients with chronic hepatitis. Gastroenterology 1992: 102; 2108-2113.
16. Rowe IW, Wands JR, Mezey E et al. Familial hemochromatosis: Characteristics of the precirrhotic stage in precirrhotic stage in a large kindred. Medicine - Baltimore 1977: 56; 197-211.
17. Brissol P, Bourel M, Herry D et al. Assessment of liver iron content in 271 patients: a reevaluation of direct and indirect methods. Gastronterology 1981: 80; 557-565.
18. Sciot R, Van Eyken Faccheti F. Hepatocellular transferrin receptor expression in secondary siderosis. Liver 1989: 9; 52-61.
19. Simmonds P, Holmes EC, Cha TA et al. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS 5 region. J. Gen. Virol. 1993: 74; 2391-2399.
20. Ferenci P, Vogel W, Pristautz H et al. One year interferon alfa (IFN-α) treatment of chronic hepatitis NANB. Hepatology 1991: 14; 72A.
21. Ferenci P. Dose increase augments the response rate to interferon alfa in chronic hepatitis C. Dig. Dis. Sci. 1996: 41; 109S- 114S.
22. NIH. Consensus statement Online 24-26 March 1997 (15-07-1997): 15 (in press).
23. Banner BF, Barton AL, Cable EE, Smith L, Bonkovsky HL. A detailed analysis of the Knodell score and other histologic parameters as predictors of response to interferon therapy in chronic hepatitis C. Mod. Pathol. 1995: 8; 232-238.
24. Scheuer PJ. Ashravzadeh P, Sherlock S et al. The pathology of hepatitis C. Hepatology 1992: 15; 567-571.
25. Yano M, Kumada H, Kage M et al. The long term pathological evolution of chronic hepatitis C. Hepatol. 1996: 23; 1334-1340.
26. Haque S, Chandra B, Gerber MA, Lok ASF. Iron overload in patients with chronic hepatitis C. A clinicopathologic study. Hum. Pathol. 1996; 27: 1277-1281.
27. Searle JW, Kerr JFR, Halliday JW, Powell LW. Iron storage disease. In McSween RNM, Anthony PP, Scheuer PJ eds. Pathology of the Liver, 2nd edn. Edinburgh: Churchill Livingston. 1989; 181-201.
28. Barton AL, Banner BF, Cable EE, Bonkovsky HL. Distribution of iron in the liver predicts the response of chronic hepatitis C infection to interferon therapy. Am. J. Clin. Pathol. 1995; 103; 419-424.
29. Farinati F, Cardin R, De Maria N et al. Iron storage, lipid peroxidation, and gluthation turnover in chronic anti-HCV positive hepatitis. J. Hepatol. 1995: 22; 449-456.
30. Caraceni P, Fagiuoli S, Van Thiel D. Iron reduction therapy: Simply camouflage, or a real weapon. Am. J. Gastroentrol. 1994: 89; 970-973.
31. Bonkovsky HL, Banner BF, Rothman AL. Iron and chronic viral hepatitis. Hepatology 1997: 25; 759-768.
32. Lustbader ED, Hann HW, Blumberg BS. Serum ferritin as a predictor of host response to hepatitis B virus infection. Science 1983: 220; 423-425.
33. Deugenier Y, Battistelli D, Jouauolle H et al. Hepatitis B virus infection markers in genetic hemochromatosis. A study of 272 patients. J. Hepatol. 1991: 13; 286-290.
34. Good MF, Powell LW. Halliday JW. Iron status and cellular immune competence. Blood Rev. 1988; 2; 43-49.
35. Bonkovsky HL. Iron and the liver. Am. J. Med. Sci. 1991: 301; 32-43.
36. Harakeh S, Jariwalla RJ, Pauling L. Suppression of human immunodeficiency virus replication by ascorbate in chronically and acutely infected cells. Proc. Natl. Acad. Sci. 1990: 87; 7245-7263.
37. Lefkowitch JH, Schiff ER, Davis GL et al. Pathological diagnosis of chronic hepatitis C. A multicenter comparative study with chronic hepatitis B. Gastroenterology 1993; 104; 595-603.
38. Czaja AJ, Carpenter HA. Sensitivity specificity, and predictability of biopsy interpretations in chronic hepatitis. Gastroenterology 1993; 105; 1824-1832.
39. Schwarz KB, Larroya S, Vogler C et al. Role of influenza B virus in hepatic steatosis and mitochondrial abnormalities in a mouse model of Reye syndrome. Hepatology 1991: 13; 96-103.
40. Dusheiko G, Schmilovitz-Weiss H, Brown D, et al. Hepatitis C virus genotypes: An investigation of type specific differences in geographic origin and disease. Hepatology 1994: 19; 13-18.